Friday, December 22, 2023 9:04:11 AM
RDGL News
New Hope In Cancer Battle: FDA Grants Breakthrough Device Status To Vivos Inc.'s RadioGel
20h
0.00%
11:58 AM EST, December 21, 2023 (Benzinga Newswire)
In a significant advancement for cancer therapy, the Food and Drug Administration (FDA) has awarded RadioGel Precision Radionuclide Therapy the coveted Breakthrough Device Designation. Developed by Vivos Inc. (OTCQB:RDGL), this designation marks a crucial milestone in the treatment of solid metastatic tumors, particularly in lymph nodes associated with papillary thyroid cancer.
How RadioGel Works
RadioGel, a pioneering Yttrium-90-based injectable brachytherapy device, represents a groundbreaking approach to cancer treatment. It is designed for patients who are either not eligible for surgery or have chosen not to undergo the procedure, particularly those with non-radioiodine avid disease and limited burden regional nodal disease.
The therapy involves directly injecting a hydrogel containing yttrium-90 phosphate microparticles into the tumor. This method allows for a more localized and potent radiation treatment compared to traditional external-beam radiation therapies.
Dr. Mike Korenko, CEO of Vivos Inc., expressed his satisfaction with the FDA's decision, citing the thorough review process and the positive results from their Risk Management Report and animal therapy data. "The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel is intrinsically safe and our animal therapy data verified its effectiveness," Korenko said.
Also Read: Biden's Million Dollar Moonshot - $240 Million Is A Boon For Cancer Research, Will it be a Boost For Pharma Stocks Too?
What's The FDA's Breakthrough Devices Program
The Breakthrough Devices Program by the FDA is designed to accelerate the development and review of innovative technologies that show potential for more effective treatment options. The program's support is instrumental in hastening patient access to promising medical advancements.
RadioGel's hydrogel technology allows for the safe delivery of higher doses necessary for treating non-resectable and radiation-resistant cancers. The product also boasts a short half-life, delivering over 90% of its therapeutic radiation within 10 days.
This feature compares favorably to other treatments that require up to six weeks for a full course of radiation therapy. Additionally, the outpatient nature of the RadioGel therapy means patients can return home without concerns about radiation exposure to family members.
With the Breakthrough Device classification, Vivos Inc. is set to expedite its Investigational Device Exemption (IDE) submission to the FDA, paving the way for human clinical trials. This collaboration with the Mayo Clinic for its initial indication marks a significant step forward in the fight against challenging cancer types, offering hope and potentially more effective treatment options to patients globally.
Now Read: Cannabis Commonly Used As Sleep Aid By Cancer Survivors, New Research Finds
Photo by National Cancer Institute on Unsplash
Write to Benzinga at editorial@benzinga.com
Recent RDGL News
- Form 8-K - Current report • Edgar (US Regulatory) • 12/27/2023 09:40:48 PM
- Form QUALIF - Notice of Qualification [Regulation A] • Edgar (US Regulatory) • 12/07/2023 05:15:10 AM
- Form 1-A POS - • Edgar (US Regulatory) • 11/27/2023 10:29:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/06/2023 04:28:46 PM
- Form 1-A POS - • Edgar (US Regulatory) • 11/03/2023 09:03:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/19/2023 04:18:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2023 10:33:58 AM
- Form 1-A POS - • Edgar (US Regulatory) • 10/10/2023 04:05:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/04/2023 07:22:21 PM
FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM
Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM